PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) CEO Sells $61,915.66 in Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) CEO David Henry Mack sold 58,411 shares of the firm's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total value of $61,915.66. Following the completion of the transaction, the chief executive officer owned 536,133 shares in the company, valued at $568,300.98. The trade was a 9.82% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

PMV Pharmaceuticals Stock Up 10.0%

Shares of PMVP traded up $0.11 during midday trading on Friday, reaching $1.21. The company had a trading volume of 582,828 shares, compared to its average volume of 197,220. PMV Pharmaceuticals, Inc. has a 1-year low of $0.81 and a 1-year high of $1.82. The stock has a market cap of $62.86 million, a PE ratio of -1.03 and a beta of 1.49. The firm has a 50 day simple moving average of $0.99 and a 200-day simple moving average of $1.19.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.03. As a group, sell-side analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Thursday, March 20th.

Institutional Trading of PMV Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp increased its stake in shares of PMV Pharmaceuticals by 23.2% in the 4th quarter. Northern Trust Corp now owns 107,340 shares of the company's stock worth $162,000 after acquiring an additional 20,190 shares during the last quarter. Aldebaran Capital LLC increased its position in shares of PMV Pharmaceuticals by 4.3% during the 1st quarter. Aldebaran Capital LLC now owns 523,553 shares of the company's stock worth $571,000 after purchasing an additional 21,363 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of PMV Pharmaceuticals by 2,282.8% during the 4th quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company's stock worth $37,000 after purchasing an additional 23,559 shares during the last quarter. Two Sigma Investments LP increased its position in shares of PMV Pharmaceuticals by 5.0% during the 4th quarter. Two Sigma Investments LP now owns 506,986 shares of the company's stock worth $766,000 after purchasing an additional 23,931 shares during the last quarter. Finally, Squarepoint Ops LLC increased its position in shares of PMV Pharmaceuticals by 68.7% during the 4th quarter. Squarepoint Ops LLC now owns 73,015 shares of the company's stock worth $110,000 after purchasing an additional 29,722 shares during the last quarter. 90.20% of the stock is owned by institutional investors and hedge funds.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.